FR17C1058I1 - - Google Patents

Info

Publication number
FR17C1058I1
FR17C1058I1 FR17C1058C FR17C1058I1 FR 17C1058 I1 FR17C1058 I1 FR 17C1058I1 FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 I1 FR17C1058 I1 FR 17C1058I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed filed Critical
Publication of FR17C1058I1 publication Critical patent/FR17C1058I1/fr
Application granted granted Critical
Publication of FR17C1058I2 publication Critical patent/FR17C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1058C 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids Active FR17C1058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
FR17C1058I1 true FR17C1058I1 (enrdf_load_stackoverflow) 2018-01-12
FR17C1058I2 FR17C1058I2 (fr) 2019-01-11

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1058C Active FR17C1058I2 (fr) 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Country Status (6)

Country Link
EP (1) EP1870096A3 (enrdf_load_stackoverflow)
BE (1) BE2017C064I2 (enrdf_load_stackoverflow)
CY (2) CY1119418T1 (enrdf_load_stackoverflow)
FR (1) FR17C1058I2 (enrdf_load_stackoverflow)
LU (1) LUC00054I2 (enrdf_load_stackoverflow)
NL (1) NL300918I2 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111011A2 (en) 2011-02-16 2012-08-23 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
EP0782445B1 (en) * 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO1997041873A1 (en) * 1996-05-07 1997-11-13 Ergo Research Corporation Method and composition for the treatment of lipid and glucose metabolism disorders
JP2002501892A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
ATE396738T1 (de) * 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
ES2325782T3 (es) * 2002-05-17 2009-09-17 Tioga Pharmaceuticals, Inc. Empleo de compuestos efectivos como moduladores selectivos de receptores de opiaceos.
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
CY1119418T1 (el) 2018-03-07
CY2017041I2 (el) 2018-09-05
FR17C1058I2 (fr) 2019-01-11
EP1870096A2 (en) 2007-12-26
NL300918I2 (nl) 2018-01-09
CY2017041I1 (el) 2018-09-05
LUC00054I2 (enrdf_load_stackoverflow) 2018-02-21
NL300918I1 (nl) 2017-12-14
BE2017C064I2 (enrdf_load_stackoverflow) 2023-08-09
LUC00054I1 (enrdf_load_stackoverflow) 2017-12-13
EP1870096A3 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
BE2013C075I2 (enrdf_load_stackoverflow)
JP2004202226A5 (enrdf_load_stackoverflow)
JP2004030586A5 (enrdf_load_stackoverflow)
JP2003326928A5 (enrdf_load_stackoverflow)
BE2013C034I2 (enrdf_load_stackoverflow)
JP2004176723A5 (enrdf_load_stackoverflow)
JP2004047954A5 (enrdf_load_stackoverflow)
JP2004005694A5 (enrdf_load_stackoverflow)
JP2004007424A5 (enrdf_load_stackoverflow)
JP2004002812A5 (enrdf_load_stackoverflow)
JP2004219126A5 (enrdf_load_stackoverflow)
LUC00054I2 (enrdf_load_stackoverflow)
JP2004145285A5 (enrdf_load_stackoverflow)
JP2003336592A5 (enrdf_load_stackoverflow)
AU2002331433A1 (enrdf_load_stackoverflow)
AU2002255066A1 (enrdf_load_stackoverflow)
AU2002256398A1 (enrdf_load_stackoverflow)
AU2002340206A1 (enrdf_load_stackoverflow)
AU2002339901A1 (enrdf_load_stackoverflow)
AU2002337949A1 (enrdf_load_stackoverflow)
AU2002333044A1 (enrdf_load_stackoverflow)
AU2002332887A1 (enrdf_load_stackoverflow)
AU2002341905A1 (enrdf_load_stackoverflow)
AU2002329412A1 (enrdf_load_stackoverflow)
AU2002327736A1 (enrdf_load_stackoverflow)